GlycoMimetics, Inc. (GLYC)
- Previous Close
1.7100 - Open
1.6800 - Bid 1.6300 x 800
- Ask 1.6500 x 700
- Day's Range
1.6250 - 1.7599 - 52 Week Range
1.1100 - 3.5300 - Volume
964,405 - Avg. Volume
467,452 - Market Cap (intraday)
105.699M - Beta (5Y Monthly) 2.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5800 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
www.glycomimetics.comRecent News: GLYC
Performance Overview: GLYC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLYC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLYC
Valuation Measures
Market Cap
105.70M
Enterprise Value
64.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.39k
Price/Book (mrq)
2.75
Enterprise Value/Revenue
6.47k
Enterprise Value/EBITDA
-1.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.55%
Return on Equity (ttm)
-90.72%
Revenue (ttm)
10k
Net Income Avi to Common (ttm)
-36.9M
Diluted EPS (ttm)
-0.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
41.79M
Total Debt/Equity (mrq)
2.10%
Levered Free Cash Flow (ttm)
-21.88M
Research Analysis: GLYC
Company Insights: GLYC
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GLYC
Daily – Vickers Top Insider Picks for 03/21/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/20/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/17/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/16/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.